Research programme: polymer therapeutics - ML Laboratories
Latest Information Update: 17 Oct 2007
At a glance
- Originator Centre for Polymer Therapeutics; ML Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
- 04 Sep 2000 Preclinical development for Cancer in United Kingdom (Unknown route)